A novel, first in class, potent, orally bioavailable, brain-penetrant, 11βHSD1 inhibitor1
• Differentiated mechanism of action: blocking cortisol production in the brain
• Symptomatic and disease modifying effects in vivo1
• Well-tolerated – dosed >100 patients/subjects: acceptable clinical safety, toxicity and PK/PD profile1
• Effective human brain concentrations demonstrated1
• XanADu – phase II clinical study underway, dosing subjects with mild AD dementia in USA, UK, AU
• Planning ongoing for additional clinical indications
• Composition of matter IP coverage ≥ 2031, patents granted in all major markets
• XanADu Alzheimer's trial fully funded following completion of ~A$5.3 million capital raise in November 2017
• A range of additional studies adequately funded following completion of ~$17 million capital raising in May 2018
Just happy they have such a strong cash position, $17m +
- Forums
- ASX - By Stock
- ACW
- Boston effect....
Boston effect...., page-57
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
8.1¢ |
Change
-0.009(10.0%) |
Mkt cap ! $218.5M |
Open | High | Low | Value | Volume |
9.0¢ | 9.2¢ | 7.9¢ | $1.117M | 13.28M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 200376 | 8.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.3¢ | 10011 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 200376 | 0.081 |
2 | 244453 | 0.080 |
4 | 707679 | 0.079 |
3 | 159875 | 0.078 |
7 | 354652 | 0.077 |
Price($) | Vol. | No. |
---|---|---|
0.083 | 10011 | 1 |
0.084 | 181122 | 3 |
0.085 | 84833 | 2 |
0.087 | 12150 | 1 |
0.088 | 60000 | 1 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |